The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer - A phase II study
The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer - A phase II study
Aims
To investigate the combination of raltitrexed and mitomycin-C as first-line chemotherapy treatment in patients with advanced colorectal cancer.
Materials and methods
A phase II study.
Results
In total, 22 patients were treated with a combination of raltitrexed 3 mg/m2 every 3 weeks and mitomycin-C 7 mg/m2 every 6 weeks for up to 24 weeks. The study was closed early for safety reasons as there were three unexpected treatment-related deaths. The overall response rate was 20%, and a further 40% achieved stable disease. The median time to progression was 3.9 months and the median overall survival time was 11.6 months.
Conclusion
Owing to the potential for increased toxicity, the combination of raltitrexed and mitomycin-C cannot be recommended as first-line treatment in patients with advanced colorectal cancer.
disease, advanced colorectal cancer, oxaliplatin, cancer, survival, raltitrexed, fluorouracil, colorectal-cancer, mitomycin-c, death, chemotherapy, 1st-line treatment, 5-fluorouracil, irinotecan
431-435
Michels, J.
01124646-b096-4cec-86c9-2cbddaad8e74
Geldart, T.
829fdbee-84dd-4825-b5eb-0e6e859ba9ff
Darby, A.
40e52ac7-914f-4fbc-b5d1-29912b81573b
Craddock, L.
4a465daa-acd0-41b1-a291-535e5addd338
Iveson, A.
0ab65b72-7381-41e1-a01a-a8513fa1f0aa
Richardson, L.
500946e3-bcc9-4dd3-950d-9a8f2e09c314
Iveson, T.
867cb6c5-ea9a-4521-a4cc-4cd4d2503b3a
August 2006
Michels, J.
01124646-b096-4cec-86c9-2cbddaad8e74
Geldart, T.
829fdbee-84dd-4825-b5eb-0e6e859ba9ff
Darby, A.
40e52ac7-914f-4fbc-b5d1-29912b81573b
Craddock, L.
4a465daa-acd0-41b1-a291-535e5addd338
Iveson, A.
0ab65b72-7381-41e1-a01a-a8513fa1f0aa
Richardson, L.
500946e3-bcc9-4dd3-950d-9a8f2e09c314
Iveson, T.
867cb6c5-ea9a-4521-a4cc-4cd4d2503b3a
Michels, J., Geldart, T., Darby, A., Craddock, L., Iveson, A., Richardson, L. and Iveson, T.
(2006)
The combination of raltitrexed (Tomudex) and mitomycin-C in the treatment of advanced colorectal cancer - A phase II study.
Clinical Oncology, 18 (6), .
(doi:10.1016/j.clon.2006.01.003).
Abstract
Aims
To investigate the combination of raltitrexed and mitomycin-C as first-line chemotherapy treatment in patients with advanced colorectal cancer.
Materials and methods
A phase II study.
Results
In total, 22 patients were treated with a combination of raltitrexed 3 mg/m2 every 3 weeks and mitomycin-C 7 mg/m2 every 6 weeks for up to 24 weeks. The study was closed early for safety reasons as there were three unexpected treatment-related deaths. The overall response rate was 20%, and a further 40% achieved stable disease. The median time to progression was 3.9 months and the median overall survival time was 11.6 months.
Conclusion
Owing to the potential for increased toxicity, the combination of raltitrexed and mitomycin-C cannot be recommended as first-line treatment in patients with advanced colorectal cancer.
This record has no associated files available for download.
More information
Published date: August 2006
Keywords:
disease, advanced colorectal cancer, oxaliplatin, cancer, survival, raltitrexed, fluorouracil, colorectal-cancer, mitomycin-c, death, chemotherapy, 1st-line treatment, 5-fluorouracil, irinotecan
Identifiers
Local EPrints ID: 62843
URI: http://eprints.soton.ac.uk/id/eprint/62843
ISSN: 0936-6555
PURE UUID: 9488415b-a11c-4bb1-96da-5630f6a30fc9
Catalogue record
Date deposited: 11 Sep 2008
Last modified: 16 Mar 2024 02:58
Export record
Altmetrics
Contributors
Author:
J. Michels
Author:
T. Geldart
Author:
A. Darby
Author:
L. Craddock
Author:
A. Iveson
Author:
L. Richardson
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
